dacarbazine has been researched along with Triple Negative Breast Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hernández, V; Martínez-Aranda, A; Modolell, I; Picón, C; Sierra, A | 1 |
| Barath, M; Chen, TC; Cho, HY; Hofman, FM; Schönthal, AH; Sharma, N; Wang, W | 1 |
| Biernat, W; Duchnowska, R; Gril, B; Hewitt, SM; Hua, E; Jassem, J; Liewehr, DJ; Palmieri, D; Qian, Y; Sosińska-Mielcarek, K; Stark, AM; Steeg, PS; Steinberg, SM; Woditschka, S | 1 |
| Borghi, D; Busel, AA; Caprera, F; Casale, E; Ciomei, M; Cirla, A; Corti, E; D'Anello, M; Donati, D; Fasolini, M; Felder, ER; Forte, B; Galvani, A; Isacchi, A; Khvat, A; Krasavin, MY; Lupi, R; Montagnoli, A; Orsini, P; Papeo, G; Perego, R; Pesenti, E; Pezzetta, D; Posteri, H; Rainoldi, S; Riccardi-Sirtori, F; Scolaro, A; Sola, F; Zuccotto, F | 1 |
| Chen, J; Chen, X; Ji, M; Jin, J; Xu, B; Xue, N; Zhou, J; Zhou, Q | 1 |
5 other study(ies) available for dacarbazine and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Development of a preclinical therapeutic model of human brain metastasis with chemoradiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Female; Green Fluorescent Proteins; Humans; Luciferases, Firefly; Mice; Mice, Nude; Neoplasms, Experimental; Radiation-Sensitizing Agents; Temozolomide; Triple Negative Breast Neoplasms | 2013 |
A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; DNA Modification Methylases; DNA Repair Enzymes; Drug Combinations; Drug Resistance, Neoplasm; Humans; Mice; Monoterpenes; Temozolomide; Triple Negative Breast Neoplasms; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2014 |
Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; MCF-7 Cells; Mice; Mice, Nude; RNA Interference; Temozolomide; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2014 |
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cell Proliferation; Dacarbazine; Drug Screening Assays, Antitumor; Female; Heterografts; High-Throughput Screening Assays; Humans; Isoindoles; Mice, Inbred BALB C; Mice, Nude; Microsomes, Liver; Models, Molecular; Neoplasm Transplantation; Pancreatic Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Rats, Sprague-Dawley; Structure-Activity Relationship; Temozolomide; Triple Negative Breast Neoplasms | 2015 |
Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Agonism; Drug Design; Female; G2 Phase; Humans; Mice, Nude; Organosilicon Compounds; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolinones; Recombinant Proteins; Temozolomide; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |